In this study, we retrospectively recruited advanced NSCLC patients with a third- or later-line regimen that uses camrelizumab monotherapy or camrelizumab plus albumin-bound paclitaxel in Jiangxi Province Cancer hospital from January 2018 to December 2021. The gene discussed is ALB; the disease is non-small cell lung carcinoma.